American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility.
about
Hereditary Cancer: Example of a Public Health Approach to Ensure Population Health Benefits of Genetic MedicineFinding all BRCA pathogenic mutation carriers: best practice modelsClinical Genetic Testing in GastroenterologyAssessing the Costs and Cost-Effectiveness of Genomic SequencingCarney complex: an updateGenetic counselors' (GC) knowledge, awareness, understanding of clinical next-generation sequencing (NGS) genomic testingAmerican Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providersFrom sample to PCR product in under 45 minutes: a polymeric integrated microdevice for clinical and forensic DNA analysis.Direct-to-Consumer Genetic and Genomic Testing: Preparing Nurse Practitioners for Genomic Healthcare.Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized MedicinePatient feedback and early outcome data with a novel tiered-binned model for multiplex breast cancer susceptibility testing.All your data (effectively) belong to us: data practices among direct-to-consumer genetic testing firms.Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting.Clinical utility of a self-administered questionnaire for assessment of hereditary gynecologic cancer.Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessmentApplication of biomarkers in cancer risk management: evaluation from stochastic clonal evolutionary and dynamic system optimization points of view.Victimized again?Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era.Melanoma genetics.Genome-wide association studies of cancer.Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.An overview of hereditary breast and ovarian cancer syndrome.Implementation and outcomes of telephone disclosure of clinical BRCA1/2 test results.Ingredients for success: a familial cancer clinic in an oncology practice setting.Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.Hereditary cancer risk assessment: essential tools for a better approach.Breast cancer genetic testing awareness, attitudes and intentions of Latinas living along the US-Mexico border: a qualitative studyFamilial colorectal cancer, beyond Lynch syndromeDevelopment of a communication protocol for telephone disclosure of genetic test results for cancer predispositionGenetic counselor opinions of, and experiences with telephone communication of BRCA1/2 test resultsDifferences in BRCA counseling and testing practices based on ordering provider type.The use of genomic information to optimize cancer chemotherapyJumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 3. Clinical Applications in the Personalized Medicine Area.Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing.Prevalence and predictors of appropriate colorectal cancer surveillance in Lynch syndrome.Physicians' current practices and opportunities for DNA banking of dying patients with cancerConfirmation of family cancer history reported in a population-based survey.Tumor genome analysis includes germline genome: are we ready for surprises?Interest in genetic testing for modest changes in breast cancer risk: implications for SNP testing.Personalized medicine: new genomics, old lessons
P2860
Q26740273-E0CD0D2B-286C-461E-823B-926085980E62Q26741854-63ABC320-F364-45A6-BDED-DAC0834287B0Q26749157-E518F38A-F8C9-4B9E-AE18-F12CA9AD9705Q26774155-247AFD5C-C53D-404B-A614-56FDA85DAAD1Q27026529-4433E577-ABAF-4589-8F39-699453E48B0DQ30205694-C053EEEB-0FA5-4BBD-8752-9803B7BDDDC3Q30416965-550C9CE0-A9FD-4508-B22C-93AF6225C992Q30456454-57F1E4E7-E9FA-4E84-97BC-98CA8BBEAA5DQ30474378-868A825C-FB12-4E06-893F-0A290A4E4CECQ30513982-5C85162A-B1AD-40B1-AD79-179328FEFBD0Q30922016-BC65EE1F-E6EC-467C-AE30-CE748BD78AB4Q31132459-F9F91452-4FBD-43D6-8A0C-7B10E50D414FQ33564013-3A2C6F54-BE9A-4763-A706-9129F7676CE4Q33647706-E23FF68D-6A35-4055-BD01-316C3734BDDFQ33796155-0F6064A7-EAA7-4DE7-92CE-B9C294B078CEQ33842160-22079618-B747-4F81-8794-39FC17D7CC80Q33846147-FDC96C1A-AE07-49DE-8BBC-B93A35189B2AQ34026161-7E7CC76C-8498-4D58-93F1-6B06E2B1CC12Q34044830-696A78C5-608A-48CB-B253-DB294C6B4024Q34193988-4F0B20A3-5F35-47EA-984E-66DCC92DF1ACQ34228853-08CEA39F-DA78-404D-AB50-AB7EDE732C98Q34305000-C0FCC789-2201-49B9-BDFF-C085B02C134DQ34351357-BB4EC55A-9A5E-4041-A91C-EEB1CA7CFE02Q34459715-1B54E721-C4F3-4599-8DE1-35CF7281F5ECQ34468665-C231B4D7-4FFA-4F07-9D40-40D3D759E46AQ34507839-974BF2AA-8B4B-4EE1-8507-4D94BCEF0EAFQ34590658-6AE0B7AF-4E0D-498A-84FF-ABF93BCB2B80Q34655489-936BCFAA-5551-408E-9C59-4A241905B54BQ34657518-7A80A866-4C21-4FE1-BB4B-513DFEEED162Q34690293-ABAE08AC-D1DF-49B1-B71A-04CAC350785DQ34691719-BE282D29-D264-4B65-8081-DE6F47C24EEAQ34791981-C712B136-DDF8-410F-A48B-436A1133AD5AQ34879739-161D0940-C18D-4817-B91F-44F1253ED340Q34921220-786005FB-0C29-4A59-B8BB-8D16569A045BQ34966336-293A338D-EE90-4896-9826-1F0D2E42AC2FQ34974920-E52CEC7A-B2EA-4140-9AF0-276357AD7AECQ34988356-66164F2A-9BA5-4839-8CD1-FDD0300976F0Q35004182-251197A9-9CB6-4F44-A06E-57A55C823399Q35016127-BA77876E-F43A-49B1-855D-979B85EF39F1Q35082635-A6745500-1986-40A0-BE71-D2E8B8B507D7
P2860
American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
American Society of Clinical O ...... ing for cancer susceptibility.
@en
American Society of Clinical O ...... ing for cancer susceptibility.
@nl
type
label
American Society of Clinical O ...... ing for cancer susceptibility.
@en
American Society of Clinical O ...... ing for cancer susceptibility.
@nl
prefLabel
American Society of Clinical O ...... ing for cancer susceptibility.
@en
American Society of Clinical O ...... ing for cancer susceptibility.
@nl
P50
P356
P1476
American Society of Clinical O ...... ing for cancer susceptibility.
@en
P2093
Courtney D Storm
Dana S Wollins
P304
P356
10.1200/JCO.2009.27.0660
P407
P577
2010-01-11T00:00:00Z